Biogen and UCB's dapirolizumab pegol for lupus shows significant reduction in disease activity in Phase 3 trial.
Biogen and UCB reported positive results from a Phase 3 trial of dapirolizumab pegol for systemic lupus erythematosus, achieving its primary endpoint. The drug demonstrated a significant reduction in disease activity when used alongside existing treatments, marking a notable success after a prior mid-stage failure. This development could provide a new option in a field with few therapies. A second Phase 3 study is set to begin in 2024.
September 24, 2024
13 Articles